Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized trial of adjuvant autologous CIK cell immunotherapy after radical hepatectomy for hepatocellular carcinoma
ChiCTR-TRC-12002093Phase 3Recruiting
- Sponsor
- Army Medical University
- Start
- Mar 2012
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of autologous cytokine-induced killer cells in hepatocellular carcinoma (HCC) (2 arms), sponsored by Army Medical University. Primary endpoints: Disease-free survival, Time to local recurrence and 1 more. Started Mar 2012; status: recruiting.
02
Drugs
autologous cytokine-induced killer cells
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-TRC-12002093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-12002093.